RE:CG Oncology NMIBC dataDonein25 ...
Via the link below, neither from any other links, I haven't been able to access their latest round of results that have been presented around Nov. 11-12.
But I found this, that help us assess market valuation and R&D spending required to get there. TLT spend much less in R&D so far. So clearly, TLT's valuation is about to catch-up in a big way. It's just a matter of time and our association with the Li Ka Shing Institute might brings us something good I assume if we get Breakthrough Therapy designation.
Nov. 17, 2022:
Oncolytic virus combinations move beyond checkpoint inhibitors Oncolytic viruses were a standout modality at the SITC 2022 conference thanks to an efficacy boost from combinations with checkpoint inhibitors, while the conference also showcased a variety of other combination partners that could represent the modality’s next frontiers.
Among the companies in the spotlight at Society for Immunotherapy of Cancer (SITC) 2022 was CG Oncology Inc., which presented Phase II data from its CG0070 oncolytic virus in combination with Keytruda pembrolizumab from Merck & Co. Inc. (NYSE:MRK). Days after the SITC presentation, CG announced it raised $120 million in an oversubscribed series E financing...
For a global perspectives though, it gives that:
Nov. 15, 2022
CG Oncology Raises $120 Million in Oversubscribed Series E Financing to Advance Clinical-Stage Urologic Oncology Pipeline The company has secured a total of over $200 million in funding to date The proceeds from the Series E financing ($120 million) will be used to advance the company’s lead clinical programs in bladder cancer towards FDA approval as well as broaden the scope of its pipeline to address unmet medical needs in urologic cancer, such as the first-line setting in Bacillus Calmette-Gurin (BCG)-nave, intermediate-risk non-muscle invasive bladder cancer (NMIBC) patients. “We have strong conviction in CG Oncology which continues to generate compelling data to develop potential bladder-sparing innovative therapeutics for patients suffering from bladder cancer,” said Simone Song, Founder and Senior Partner of ORI Capital. “We’ve been strong supporters of the CG Oncology team from an early stage by leading the Series C round, and we are particularly proud to co-lead this round with Longitude Capital and Decheng Capital, as we see tremendous potential for CG0070 to be a game changer for patients with NMIBC.”
“In advanced clinical studies CG0070 has continued to demonstrate potentially transformational results in patients with bladder cancer unresponsive to BCG, a difficult-to-treat patient population,” said Brian Liu, M.D., Principal, Longitude Capital. “I am excited to join CG Oncology’s board of directors during this significant expansion trajectory for the company and am looking forward to working with the leadership team to bring this therapy to patients in need.”
CG0070 has been administered to over 200 patients for the treatment of bladder cancer. The investigational therapy has exhibited potential best-in-class efficacy and safety in monotherapy as well as strong response rates when combined with checkpoint inhibitors. Given CG0070’s combination results with strong complete response rates in heavily pre-treated BCG-unresponsive, high-risk NMIBC patients, there has been significant demand within the urologic community for CG0070 to also be investigated in the BCG-nave NMIBC setting, where limited treatment options have been exacerbated by the global BCG shortage impacting both providers and patients. In response, CG Oncology has decided to investigate the activity of CG0070 as a first-line treatment of BCG-nave, intermediate-risk NMIBC in a Phase 2 study to expand clinical development for additional patients with bladder cancer.